SS-31 peptide

SS-31 peptide is a peptide compound being studied for its potential anti-aging and longevity-promoting properties that has attracted attention in both research and clinical settings. Understanding its mechanism of action, research history, and current evidence base is essential for anyone evaluating it for research purposes.

This section provides a high-level overview based on published peer-reviewed literature. For detailed protocol information, dosing ranges reported in studies, and the latest research papers, see the sections below or visit the full entry in our Peptide Encyclopedia.

SS-31 peptide exerts its effects through specific molecular pathways that have been characterized in preclinical and, in some cases, clinical research. Understanding how a peptide works at the cellular level is critical for evaluating its potential applications and limitations.

SS-31 peptide is proposed to act on pathways associated with cellular aging, including telomere maintenance, mitochondrial function, senescent cell clearance, or NAD+ metabolism. Research in this area is evolving, with preclinical data suggesting effects on biomarkers associated with biological aging. Human clinical validation of these mechanisms is ongoing.

The research landscape for ss-31 peptide includes both preclinical studies (cell culture, animal models) and, in some cases, human clinical trials. It's important to distinguish between these levels of evidence when evaluating any peptide's potential.

Key research findings for SS-31 peptide span multiple study types, from in vitro cellular assays to animal models and, where available, human clinical trials. The strength of evidence varies — it's important to note which findings come from controlled human trials versus preclinical work when evaluating any peptide's potential. Browse our research paper database for the latest published studies on ss-31 peptide.

• Preclinical studies have demonstrated measurable biological effects in relevant models
• Research interest has remained active based on publication volume
• Multiple research groups across different institutions have published findings
• Human clinical data is available for some applications
• Safety and tolerability data from published studies supports further investigation

Dosing information below is compiled from published research studies and is provided for educational reference only. Protocols vary significantly between studies, and individual responses differ based on numerous biological factors.

Research protocols for SS-31 peptide vary across published studies. Common variables include dosage (often reported in mcg/kg or mg), administration route (subcutaneous, intramuscular, oral, or intranasal), frequency (daily, every other day, or cycling protocols), and duration (typically 4–12 weeks in research settings). Always reference the original study protocol for context when evaluating dosing data.

Understanding the safety profile of ss-31 peptide requires reviewing reported adverse events across published studies. Side effect profiles can vary based on dosage, route of administration, duration of use, and individual health factors.

The safety profile of ss-31 peptide is based on available published data, which may be limited. As with any bioactive compound, individual responses vary and dose-dependent effects are expected. Long-term safety data may not be available for all peptides. Always start with the lowest effective dose and monitor for adverse reactions.

• Side effect profiles vary by compound, dose, and individual biology
• Injection site reactions (redness, swelling) are commonly reported for injectable peptides
• Dose-dependent effects are typical — start low and titrate gradually
• Long-term safety data may be limited for some research peptides
• Drug interactions should be evaluated, especially with hormonal or immunological medications
• Contraindications may include pregnancy, active cancer, or certain autoimmune conditions

The regulatory status of ss-31 peptide varies by jurisdiction and is subject to change. In the United States, peptide regulations are evolving rapidly following the FDA's 2024 Category 2 designations and subsequent policy shifts in 2025–2026.

As of May 2026, 14 of 19 previously restricted Category 2 peptides are expected to return to Category 1 status, pending formal FDA reclassification. Check our regulatory tracker and official FDA resources for the most current status of specific compounds.

When researching ss-31 peptide, the quality of your source material directly impacts the validity and safety of your work. PeptideVault's vendor directory provides objective vetting scores based on GMP certification, COA verification, business registration, and community reviews.

Always request a recent Certificate of Analysis (COA) from a third-party lab showing HPLC purity, mass spectrometry confirmation, and endotoxin testing for injectable-grade products. Compare multiple vendors before purchasing.

• Verify >98% HPLC purity on the Certificate of Analysis
• Confirm molecular weight via mass spectrometry matches the target peptide
• Check for endotoxin and sterility testing on injectable products
• Compare pricing across multiple GMP-certified vendors
• Read community reviews on PeptideVault before purchasing